334 related articles for article (PubMed ID: 25043542)
1. [Efficacy studies].
Pedro-Botet J; Flores-Le Roux JA
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
[TBL] [Abstract][Full Text] [Related]
2. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Farnier M
Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
[TBL] [Abstract][Full Text] [Related]
4. [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Hernández Mijares A
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():25-30. PubMed ID: 25043544
[TBL] [Abstract][Full Text] [Related]
5. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
6. [Achievement of therapeutic objectives].
Mantilla T
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():20-4. PubMed ID: 25043543
[TBL] [Abstract][Full Text] [Related]
7. [Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Pintó X
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():35-9. PubMed ID: 25043546
[TBL] [Abstract][Full Text] [Related]
8. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Filippatos TD; Elisaf MS
Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529
[TBL] [Abstract][Full Text] [Related]
11. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
12. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
[TBL] [Abstract][Full Text] [Related]
14. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
[TBL] [Abstract][Full Text] [Related]
15. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
17. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Pérez A
Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
[No Abstract] [Full Text] [Related]
18. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Farnier M; Steinmetz A; Retterstøl K; Császár A
Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
[TBL] [Abstract][Full Text] [Related]
20. [Reasons for a combination].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
